It has been found that the effects of the metabolic syndrome such as obesity, fatty liver, insulin resistance, glucose intolerance can be decreased by complete ChREBP inhibition can as seen in ob/ob mice [27]. This evidence concerns the gene MLXIPL and fatty liver disease.